Payment overview · 2025
General Payments
$406.90
18 reported records · 7 companies
Healthcare provider profile · identity verified
Marion Lee Gardner, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH PLAINS, OR · NPI 1740382480
Verified facts
What the public records show
CMS Open Payments records show Marion Lee Gardner, MD received $406.90 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.88 | 52.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.23 | 15.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.71 | 10.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.20 | 9.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $23.30 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.45 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.13 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.90 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $194.38 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.23 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 344 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 111 |
| Metformin Hcl | Metformin Hcl | 310 | 92 |
| Omeprazole | Omeprazole | 282 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 74 |
| Lisinopril | Lisinopril | 236 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 62 |
| Gabapentin | Gabapentin | 224 | 62 |
| Furosemide | Furosemide | 143 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 43 |
| Potassium Chloride | Potassium Chloride | 130 | 38 |
| Trazodone Hcl | Trazodone Hcl | 127 | 33 |
| Glipizide | Glipizide | 120 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 26 |
| Prednisone | Prednisone | 110 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 31 |
| Eliquis | Apixaban | 91 | 26 |
| Valsartan | Valsartan | 91 | 28 |
| Ezetimibe | Ezetimibe | 90 | 27 |
| Famotidine | Famotidine | 90 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Spironolactone | Spironolactone | 79 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 19 |
| Aripiprazole | Aripiprazole | 68 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 16 |
| Simvastatin | Simvastatin | 67 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 28 |
| Mirtazapine | Mirtazapine | 62 | 13 |
| Risperidone | Risperidone | 59 | 12 |
| Sertraline Hcl | Sertraline Hcl | 59 | 15 |
| Myrbetriq | Mirabegron | 56 | 11 |
| Clonidine Hcl | Clonidine Hcl | 55 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 28 |
| Mupirocin | Mupirocin | 53 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Cephalexin | Cephalexin | 51 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 38 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Montelukast Sodium | Montelukast Sodium | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 48 | 22 |
| Memantine Hcl | Memantine Hcl | 47 | 15 |
| Ozempic | Semaglutide | 46 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | 21 |
| Carvedilol | Carvedilol | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | 12 |
| Finasteride | Finasteride | 43 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 14 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | 13 |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Atenolol | Atenolol | 35 | 15 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | 19 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 19 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Clotrimazole | Clotrimazole | 25 | 15 |
| Ketoconazole | Ketoconazole | 25 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Probenecid | Probenecid | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.90 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, GRAFIX PL, NURTEC ODT, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error